{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["300(4)"],"submitter":["Zhang C"],"funding":["Jiangxi Provincial Natural Science Foundation","National Natural Science Foundation of China"],"pubmed_abstract":["Transforming growth factor-β (TGF-β) and Hippo signaling are two critical pathways engaged in cancer progression by regulating both oncogenes and tumor suppressors, yet how the two pathways coordinately exert their functions in the development of hepatocellular carcinoma (HCC) remains elusive. In this study, we firstly conducted an integrated analysis of public liver cancer databases and our experimental TGF-β target genes, identifying CYR61 as a pivotal candidate gene relating to HCC development. The expression of CYR61 is downregulated in clinical HCC tissues and cell lines than that in the normal counterparts. Evidence revealed that CYR61 is a direct target gene of TGF-β in liver cancer cells. In addition, TGF-β-stimulated Smad2/3 and the Hippo pathway downstream effectors YAP and TEAD4"],"journal":["The Journal of biological chemistry"],"pagination":["107208"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11021963"],"repository":["biostudies-literature"],"pubmed_title":["Upregulation of CYR61 by TGF-β and YAP signaling exerts a counter-suppression of hepatocellular carcinoma."],"pmcid":["PMC11021963"],"pubmed_authors":["Li C","Luo Z","Hao L","Wei W","Yan X","Liang B","Dai X","Li Y","Tu S","Zheng L","Luo W","Chen YG","Zhang C","Wang Y","Wu Y"],"additional_accession":[]},"is_claimable":false,"name":"Upregulation of CYR61 by TGF-β and YAP signaling exerts a counter-suppression of hepatocellular carcinoma.","description":"Transforming growth factor-β (TGF-β) and Hippo signaling are two critical pathways engaged in cancer progression by regulating both oncogenes and tumor suppressors, yet how the two pathways coordinately exert their functions in the development of hepatocellular carcinoma (HCC) remains elusive. In this study, we firstly conducted an integrated analysis of public liver cancer databases and our experimental TGF-β target genes, identifying CYR61 as a pivotal candidate gene relating to HCC development. The expression of CYR61 is downregulated in clinical HCC tissues and cell lines than that in the normal counterparts. Evidence revealed that CYR61 is a direct target gene of TGF-β in liver cancer cells. In addition, TGF-β-stimulated Smad2/3 and the Hippo pathway downstream effectors YAP and TEAD4","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2026-06-01T11:54:04.674Z","creation":"2026-04-08T12:06:18.146Z"},"accession":"S-EPMC11021963","cross_references":{"pubmed":["38521502"],"doi":["10.1016/j.jbc.2024.107208"]}}